Squarepoint
GMAB icon

Squarepoint’s Genmab GMAB Stock Holding History

Squarepoint’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$204K Sell
7,421
-27,112
-79% -$721K ﹤0.01% 4056
2026
Q1 		$927K Buy
+34,533
New +$1.03M ﹤0.01% 2830
2025
Q4 		– Sell
-9,480
Closed -$291K – 4492
2025
Q3 		$291K Sell
9,480
-84,753
-90% -$2.07M ﹤0.01% 3695
2025
Q2 		$1.95M Buy
94,233
+81,434
+636% +$1.67M ﹤0.01% 2124
2025
Q1 		$251K Sell
12,799
-104,708
-89% -$2.2M ﹤0.01% 3861
2024
Q4 		$2.45M Buy
117,507
+108,705
+1,235% +$2.39M ﹤0.01% 2238
2024
Q3 		$215K Buy
+8,802
New +$235K ﹤0.01% 3643
2024
Q2 		– Sell
-19,116
Closed -$572K – 4275
2024
Q1 		$572K Buy
19,116
+1,353
+8% +$39.7K ﹤0.01% 2955
2023
Q4 		$566K Buy
17,763
+5,550
+45% +$174K ﹤0.01% 2912
2023
Q3 		$431K Sell
12,213
-7,766
-39% -$296K ﹤0.01% 2905
2023
Q2 		$759K Buy
19,979
+1,235
+7% +$49.2K ﹤0.01% 2366
2023
Q1 		$708K Sell
18,744
-1,467
-7% -$56.4K ﹤0.01% 2106
2022
Q4 		$857K Sell
20,211
-26,979
-57% -$1.11M ﹤0.01% 1925
2022
Q3 		$1.52M Buy
+47,190
New +$1.66M 0.01% 1498
2021
Q1 		– Sell
-9,231
Closed -$375K – 3294
2020
Q4 		$375K Buy
+9,231
New +$345K ﹤0.01% 2040

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Squarepoint's GMAB Position: Q2 2026 in Review

Squarepoint reduced its Genmab (GMAB) stake by 79% in Q2 2026, selling an estimated $721K and leaving 7,421 shares worth $204K. The position accounts for ﹤0.01% of the portfolio, ranked #4056.

Squarepoint first reported a position in GMAB in Q4 2020 and has held it in 15 quarters since. The position peaked at $2.45M in Q4 2024. 292 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Squarepoint held 7,421 shares of Genmab worth $204K as of Q2 2026.
  • Squarepoint sold 27,112 Genmab shares in Q2 2026, an estimated $721K.
  • Genmab made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #4056 holding.
  • Squarepoint first reported a position in Genmab in Q4 2020 and has held it in 15 quarters since.
  • Squarepoint's Genmab position peaked at $2.45M in Q4 2024.
  • 292 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.